8 results
Primary objective: To evaluate the non-inferiority of QVA149 110/50 µg qd as compared to concurrentadministration of QAB149 150 µg qd plus NVA237 50 µg qd in terms of its effect on trough FEV1 (mean of 23 h 15 min and 23 h 45 min post-dose)…
The aim of this study is to prove the efficacy of 3 times daily 1 mg glycopyrronium bromide versus placebo in patients with PD with hypersalivation. Furthermore, the safety of glycopyrronium bromide used in the mentioned dosage will be further…
The primary objective is to investigate the safety and tolerability of inhalation of glycopyrronium inhalation powder using different dosing regimens. The second objectives are to determine the decrease in drooling by using different dosing regimens…
To examine the effects of mono- and combination therapy with linagliptin and empagliflozine on renal hemodynamics
The main objective of this study is to assess whether in-hospital administration of empagliflozin results in improvement in HF-related outcomes in patients hospitalised for acute heart failure (de novo or decompensated chronic HF) and after initial…
Primary: To demonstrate the superiority of NVA237 50 *g o.d. compared to placebo in addition to background therapy with long acting B2 agonist/ inhaled corticosteroid (* 800 *g/day of budesonide or equivalent) in terms of trough FEV1 after 26 weeks…
To determine if inhibition with GPB can provide a significant reduction in the accumulation of systemically administered Ga-PSMA in salivary glands on PET/CT, with the aim to determine if GPB can prevent toxicity from Lu-PSMA or other…
To investigate the potential of preoperative initiation (7 days) and perioperative continuation (until day 2 after surgery) of empagliflozin 10 mg daily to reduce the acute kidney injury marker neutrophil gelatinase-associated lipocalin (NGAL) on…